Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Horizon Discovery announces partnership with Human Protein Atlas

By Chris Newmarker | December 4, 2019

Horizon Discovery GroupHorizon Discovery Group (LSE: HZD) announced this week that the Human Protein Atlas will use Horizon’s CRISPR-edited knockout cell models to further expand the knowledge available in its Cell Atlas program.

Horizon specialized in the application of gene editing and gene modulation for cell line engineering. Knockout cell models offer the possibility for an enhanced validation of antibodies based on genetic strategies. That’s because the complete absence of the targeting protein correlates with a complete loss of signal for specific antibodies, according to the company.

Adding more validation data for the Human Protein Atlas’ antibodies will increase the reliability of the Cell Atlas and thereby help users find the most trustworthy tools for their research, Cambridge, U.K.–based Horizon said.

HPA, based in Sweden, started in 2003 with the goal of mapping all human proteins in cells, tissues and organs — with an open-access database for academia and industry. HPA researchers will start out by utilizing 500 of Horizon’s CRISPR-edited knockout cell models as part of large-scale protein expression and imaging studies.

“Horizon has over a decade of experience in gene editing, and a well-established reputation for providing CRISPR-edited knockout cell models,” said Emma Lundberg, the head of the HPA Cell Atlas program. “We have previously used Horizon’s cell lines in our high throughput imaging processes with great success. Using a validated gene-edited cell line where all cell models have the same background will be key to maximizing efficiency and achieving data reproducibility.”

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Vertex Pharmaceuticals
Vertex Pharmaceuticals wins FDA fast track designation for its cell-based diabetes treatment
Alzheimer's disease
How to build a foundation for the next phase of Alzheimer’s disease research
Brain radiological image
Why Genuity and Emory are partnering on neurodegenerative disease research
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards